Skip Navigation Links
Skip Navigation Links


MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.  EAY131 (NCT02465050)  (MBMC Contact: Chris Joyce 314-9916-5536)


Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients with advanced G3 non-small cell gastroentropancreatic neuroendocrine carcinomas  ECOG/ACRIN 2142 (NCT02595424)  (MBMC Contact:  Henry Robinson 996-5865)

Randomized Phase III trial of mematine and whole-brain radiotherapy with or without hippocampal avoidance in patients with brain metastases  NRG-CC001 (NCT02360215 )  (MBMC Contact:  Diana Christian 314-996-5888)  (Requires radiation oncologist to undergo training and specialized MRIs - approved at MBMC)


Neuroendocrine Trials in St. Louis, MO

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy